Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE.

Oncotarget. 2017 Dec 31;9(6):6659-6677. doi: 10.18632/oncotarget.23795. eCollection 2018 Jan 23.

2.

A rare case of Candida parapsilosis osteomyelitis: a literature review and proposed treatment algorithm.

Yingling JM, Sun L, Yoon R, Liporace F.

Patient Saf Surg. 2017 Dec 21;11:31. doi: 10.1186/s13037-017-0146-9. eCollection 2017.

3.

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.

Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, Yingling JM, Lahn MM.

Br J Clin Pharmacol. 2014 May;77(5):796-807.

4.

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM.

Bone. 2012 Mar;50(3):695-703. doi: 10.1016/j.bone.2011.11.022. Epub 2011 Dec 7.

5.

Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.

Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ.

Cancer Res. 2011 Mar 15;71(6):2339-49. doi: 10.1158/0008-5472.CAN-10-2941. Epub 2011 Jan 31.

6.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR.

Cancer Res. 2011 Mar 1;71(5):1849-57. doi: 10.1158/0008-5472.CAN-10-3298. Epub 2011 Jan 13.

7.

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A.

Cancer Res. 2011 Feb 1;71(3):955-63. doi: 10.1158/0008-5472.CAN-10-2933. Epub 2010 Dec 28. Erratum in: Cancer Res. 2011 Apr 1;71(7):2806. Mantzaris, Giannis [corrected to Mantzaris, Ioannis].

8.

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.

Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, Baselga J, Seoane J.

Cancer Cell. 2010 Dec 14;18(6):655-68. doi: 10.1016/j.ccr.2010.10.023.

9.

Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M.

Mol Cancer. 2010 May 26;9:122. doi: 10.1186/1476-4598-9-122.

10.

Smad7 regulates the adult neural stem/progenitor cell pool in a transforming growth factor beta- and bone morphogenetic protein-independent manner.

Krampert M, Chirasani SR, Wachs FP, Aigner R, Bogdahn U, Yingling JM, Heldin CH, Aigner L, Heuchel R.

Mol Cell Biol. 2010 Jul;30(14):3685-94. doi: 10.1128/MCB.00434-09. Epub 2010 May 17.

11.

Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases.

O'Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M.

Biologics. 2008 Sep;2(3):563-9.

12.

Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model.

Chen Y, Wei T, Yan L, Lawrence F, Qian HR, Burkholder TP, Starling JJ, Yingling JM, Shou J.

BMC Genomics. 2008 Jun 2;9:264. doi: 10.1186/1471-2164-9-264.

13.

Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype.

Bharathy S, Xie W, Yingling JM, Reiss M.

Cancer Res. 2008 Mar 15;68(6):1656-66. doi: 10.1158/0008-5472.CAN-07-5089.

14.

Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS, Huss KL, Voss MD, Wang Y, Clawson DK, Yingling JM, Sawyer JS.

J Med Chem. 2008 Apr 10;51(7):2302-6. doi: 10.1021/jm701199p. Epub 2008 Mar 4.

PMID:
18314943
15.

TGF-beta signalling-related markers in cancer patients with bone metastasis.

Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M.

Biomarkers. 2008 Mar;13(2):217-36. doi: 10.1080/13547500701676019 .

PMID:
18270872
16.

Analysis of pathway activity in primary tumors and NCI60 cell lines using gene expression profiling data.

Feng XD, Huang SG, Shou JY, Liao BR, Yingling JM, Ye X, Lin X, Gelbert LM, Su EW, Onyia JE, Li SY.

Genomics Proteomics Bioinformatics. 2007 Feb;5(1):15-24.

17.

Development and validation of a phosphorylated SMAD ex vivo stimulation assay.

Farrington DL, Yingling JM, Fill JA, Yan L, Qian YW, Shou J, Wang X, Ehsani ME, Cleverly AL, Daly TM, Lahn M, Konrad RJ, Ray CA.

Biomarkers. 2007 May-Jun;12(3):313-30.

PMID:
17453744
18.
19.

Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.

Shiou SR, Datta PK, Dhawan P, Law BK, Yingling JM, Dixon DA, Beauchamp RD.

J Biol Chem. 2006 Nov 10;281(45):33971-81. Epub 2006 Sep 7.

20.

Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

Li HY, Wang Y, Heap CR, King CH, Mundla SR, Voss M, Clawson DK, Yan L, Campbell RM, Anderson BD, Wagner JR, Britt K, Lu KX, McMillen WT, Yingling JM.

J Med Chem. 2006 Mar 23;49(6):2138-42.

PMID:
16539403
21.

Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression.

Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL.

Oncogene. 2006 Jun 8;25(24):3408-23. Epub 2005 Sep 26.

PMID:
16186809
22.

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.

Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N, Sawyer JS, Yingling JM.

Biochemistry. 2005 Feb 22;44(7):2293-304.

PMID:
15709742
23.

Development of TGF-beta signalling inhibitors for cancer therapy.

Yingling JM, Blanchard KL, Sawyer JS.

Nat Rev Drug Discov. 2004 Dec;3(12):1011-22. Review.

PMID:
15573100
24.

Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).

Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM.

Curr Opin Drug Discov Devel. 2004 Jul;7(4):437-45. Review.

PMID:
15338953
25.

Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.

Li HY, Wang Y, Yan L, Campbell RM, Anderson BD, Wagner JR, Yingling JM.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3585-8.

PMID:
15177480
26.

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3581-4.

PMID:
15177479
27.

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM.

J Med Chem. 2003 Sep 11;46(19):3953-6.

PMID:
12954047
28.

Bmp signaling regulates proximal-distal differentiation of endoderm in mouse lung development.

Weaver M, Yingling JM, Dunn NR, Bellusci S, Hogan BL.

Development. 1999 Sep;126(18):4005-15.

29.

Epithelial/mesenchymal interactions and branching morphogenesis of the lung.

Hogan BL, Yingling JM.

Curr Opin Genet Dev. 1998 Aug;8(4):481-6. Review.

PMID:
9729726
30.

Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein.

Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT, Wang XF.

Mol Cell Biol. 1997 Dec;17(12):7019-28.

31.

Smad5 induces ventral fates in Xenopus embryo.

Suzuki A, Chang C, Yingling JM, Wang XF, Hemmati-Brivanlou A.

Dev Biol. 1997 Apr 15;184(2):402-5.

32.

Mammalian dwarfins are phosphorylated in response to transforming growth factor beta and are implicated in control of cell growth.

Yingling JM, Das P, Savage C, Zhang M, Padgett RW, Wang XF.

Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):8940-4.

33.

Signaling by the transforming growth factor-beta receptors.

Yingling JM, Wang XF, Bassing CH.

Biochim Biophys Acta. 1995 Dec 18;1242(2):115-36. Review. No abstract available.

PMID:
7492567
34.

A transforming growth factor beta type I receptor that signals to activate gene expression.

Bassing CH, Yingling JM, Howe DJ, Wang T, He WW, Gustafson ML, Shah P, Donahoe PK, Wang XF.

Science. 1994 Jan 7;263(5143):87-9.

PMID:
8272871
35.

Receptors for the TGF-beta ligand family.

Bassing CH, Yingling JM, Wang XF.

Vitam Horm. 1994;48:111-56. Review. No abstract available.

PMID:
7941425
36.
37.

An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.

Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC.

Mol Cell Endocrinol. 1992 Dec;90(1):77-86.

PMID:
1301400

Supplemental Content

Loading ...
Support Center